Tisotumab vedotin联合方案治疗复发或转移性宫颈癌的5年结果
innovaTV 205/ENGOT-cx8/GOG-3024研究评估了基于Tisotumab vedotin(TV)的联合方案在复发或转移性宫颈癌(r/mCC)一线(1L)及经治(2L+)的疗效与安全性。截至2025年10月15日,剂量扩展组共139例患者,1L TV+卡铂+帕博利珠单抗±贝伐珠单抗组(H组)确认ORR达65.8%,中位PFS 10.6个月,中位OS 28.0个月,≥3级治疗相关不良事件发生率为86.8%。
要点
- TV联合卡铂和帕博利珠单抗(±贝伐珠单抗)在1L r/mCC中显示高缓解率和持久生存获益。
- TV双药联合在1L和2L+ r/mCC中均显示与既往一致的持久抗肿瘤活性。
- 含TV联合方案的安全性总体可控,未观察到新的安全信号,但3级及以上不良事件常见。
核心结论
- 经过至少5年随访,基于TV的双药联合方案在1L和2L+ r/mCC中显示出与既往一致的持久抗肿瘤活性及鼓舞人心的长期OS,未发现新的安全信号。
- 1L含TV的三药/四药联合方案显示出有意义的抗肿瘤活性,毒性符合预期。
研究设计与样本
- innovaTV 205/ENGOT-cx8/GOG-3024(NCT03786081)是一项多中心、开放标签1b/2期研究。
- 剂量扩展组包括1L TV+卡铂(D组,n=33)、1L/2L+ TV+帕博利珠单抗(E组n=33,F组n=35)及1L TV+卡铂+帕博利珠单抗±贝伐珠单抗(H组,n=38),共139例患者。
- 主要终点为研究者根据RECIST v1.1评估的客观缓解率(ORR),次要终点包括缓解持续时间(DOR)、无进展生存期(PFS)、总生存期(OS)及不良事件(AE)。
主要发现
- D、E、F、H组的确认ORR分别为54.5%、40.6%、35.3%和65.8%;中位DOR分别为8.6个月、未达到、18.2个月和13.3个月。
- D、E、F、H组的中位PFS分别为6.9、5.3、5.6和10.6个月;中位OS分别为25.5、30.7、15.3和28.0个月。
- D、E、F、H组中任何治疗成分相关的≥3级AE发生率分别为72.7%、45.5%、48.6%和86.8%;导致TV停药的不良事件发生率分别为24.2%、24.2%、34.3%和55.3%。
临床怎么用
- 对于1L r/mCC患者,含TV的三药或四药联合方案(如TV+卡铂+帕博利珠单抗±贝伐珠单抗)可考虑作为治疗选择,但需密切监测毒性。
- TV双药联合方案在1L和2L+ r/mCC中具有持久活性,可作为复发或转移性宫颈癌的潜在治疗策略。
局限性
- 本研究为1b/2期单臂剂量扩展研究,样本量较小,缺乏随机对照,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment options for recurrent or metastatic cervical cancer (r/mCC) remain limited. We evaluated the efficacy and safety of tisotumab vedotin (TV)-based combinations with standard agents in first-line (1L) and previously treated (second-line or later [2L+]) settings in r/mCC. METHODS: innovaTV 205/ENGOT-cx8/GOG-3024 (NCT03786081) was a multicenter, open-label phase 1b/2 study, which included dose-expansion arms of 1L TV + carboplatin (arm D), 1L/2L+ TV + pembrolizumab (arms E/F), and 1L TV + carboplatin + pembrolizumab ± bevacizumab (arm H). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). RESULTS: As of October 15, 2025, 139 patients were enrolled in dose-expansion arms D (n = 33), E (n = 33), F (n = 35), and H (n = 38). Confirmed ORR (median DOR) was 54.5% (8.6 months), 40.6% (not reached), 35.3% (18.2 months), and 65.8% (13.3 months) in arms D-F and H, respectively. Median PFS was 6.9, 5.3, 5.6, and 10.6 months; median OS was 25.5, 30.7, 15.3, and 28.0 months. Grade ≥ 3 AEs related to any treatment component occurred in 72.7%, 45.5%, 48.6%, and 86.8% of patients; AEs leading to TV discontinuation occurred in 24.2%, 24.2%, 34.3%, and 55.3% of patients in arms D-F and H, respectively. CONCLUSION: With ≥ 5 years of follow-up, TV doublet combinations demonstrated durable activity consistent with previous findings and encouraging long-term OS in 1L and 2L+ r/mCC, with no new safety signals. The 1L TV-based triplet/quadruplet regimen showed meaningful antitumor activity with expected toxicity.
引用
- Van Nieuwenhuysen E, Vergote I, Randall LM, et al. Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study. Gynecol Oncol. 2026. PMID: 42000372. doi:10.1016/j.ygyno.2026.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。